{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,3,11]],"date-time":"2026-03-11T20:15:28Z","timestamp":1773260128514,"version":"3.50.1"},"reference-count":42,"publisher":"MDPI AG","issue":"4","license":[{"start":{"date-parts":[[2020,4,14]],"date-time":"2020-04-14T00:00:00Z","timestamp":1586822400000},"content-version":"vor","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by\/4.0\/"}],"content-domain":{"domain":[],"crossmark-restriction":false},"short-container-title":["Viruses"],"abstract":"<jats:p>A new Coronavirus strain, named SARS-CoV-2, suddenly emerged in early December 2019. SARS-CoV-2 resulted in being dramatically infectious, with thousands of people infected. In this scenario, and without effective vaccines available, the importance of an immediate tool to support patients and against viral diffusion becomes evident. In this study, we exploit the molecular docking approach to analyze the affinity between different viral proteins and several inhibitors, originally developed for other viral infections. Our data show that, in some cases, a relevant binding can be detected. These findings support the hypothesis to develop new antiviral agents against COVID-19, on the basis of already established therapies.<\/jats:p>","DOI":"10.3390\/v12040445","type":"journal-article","created":{"date-parts":[[2020,4,15]],"date-time":"2020-04-15T04:01:46Z","timestamp":1586923306000},"page":"445","update-policy":"https:\/\/doi.org\/10.3390\/mdpi_crossmark_policy","source":"Crossref","is-referenced-by-count":100,"title":["Molecular Investigation of SARS\u2013CoV-2 Proteins and Their Interactions with Antiviral Drugs"],"prefix":"10.3390","volume":"12","author":[{"given":"Paolo","family":"Calligari","sequence":"first","affiliation":[{"name":"Department of Chemical Sciences and Technologies, University of Rome Tor Vergata, Via della Ricerca Scientifica 1, 00133 Rome, Italy"}],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Sara","family":"Bobone","sequence":"additional","affiliation":[{"name":"Department of Chemical Sciences and Technologies, University of Rome Tor Vergata, Via della Ricerca Scientifica 1, 00133 Rome, Italy"}],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Giorgio","family":"Ricci","sequence":"additional","affiliation":[{"name":"Department of Chemical Sciences and Technologies, University of Rome Tor Vergata, Via della Ricerca Scientifica 1, 00133 Rome, Italy"}],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Alessio","family":"Bocedi","sequence":"additional","affiliation":[{"name":"Department of Chemical Sciences and Technologies, University of Rome Tor Vergata, Via della Ricerca Scientifica 1, 00133 Rome, Italy"}],"role":[{"role":"author","vocabulary":"crossref"}]}],"member":"1968","published-online":{"date-parts":[[2020,4,14]]},"reference":[{"key":"ref_1","doi-asserted-by":"crossref","first-page":"151","DOI":"10.1016\/j.mam.2007.09.005","article-title":"Ebolavirus and Marburgvirus: Insight the Filoviridae family","volume":"29","author":"Ascenzi","year":"2008","journal-title":"Mol. Asp. Med."},{"key":"ref_2","doi-asserted-by":"crossref","unstructured":"Schwartz, D.A., and Graham, A.L. (2020). Potential Maternal and Infant Outcomes from (Wuhan) Coronavirus 2019-nCoV Infecting Pregnant Women: Lessons from SARS, MERS, and Other Human Coronavirus Infections. Viruses, 12.","DOI":"10.3390\/v12020194"},{"key":"ref_3","doi-asserted-by":"crossref","first-page":"1123","DOI":"10.1016\/j.bbamem.2019.03.013","article-title":"Structural determinants of the interaction between influenza A virus matrix protein M1 and lipid membranes","volume":"1861","author":"Dahmani","year":"2019","journal-title":"Biochim. Biophys. Acta Biomembr."},{"key":"ref_4","doi-asserted-by":"crossref","first-page":"e00267-17","DOI":"10.1128\/JVI.00267-17","article-title":"Phosphatidylserine Lateral Organization Influences the Interaction of Influenza Virus Matrix Protein 1 with Lipid Membranes","volume":"91","author":"Bobone","year":"2017","journal-title":"J. Virol."},{"key":"ref_5","doi-asserted-by":"crossref","first-page":"10","DOI":"10.1021\/ci049809b","article-title":"Virtual screening of novel noncovalent inhibitors for SARS-CoV 3C-like proteinase","volume":"45","author":"Liu","year":"2005","journal-title":"J. Chem. Inf. Model."},{"key":"ref_6","doi-asserted-by":"crossref","first-page":"221","DOI":"10.1080\/22221751.2020.1719902","article-title":"Genomic characterization of the 2019 novel human-pathogenic coronavirus isolated from a patient with atypical pneumonia after visiting Wuhan","volume":"9","author":"Chan","year":"2020","journal-title":"Emerg. Microb. Infect."},{"key":"ref_7","doi-asserted-by":"crossref","first-page":"e00127-20","DOI":"10.1128\/JVI.00127-20","article-title":"Receptor recognition by novel coronavirus from Wuhan: An analysis based on decade-long structural studies of SARS","volume":"94","author":"Wan","year":"2020","journal-title":"J. Virol."},{"key":"ref_8","doi-asserted-by":"crossref","first-page":"2515","DOI":"10.1128\/JVI.02114-07","article-title":"Structures of two coronavirus main proteases: Implications for substrate binding and antiviral drug design","volume":"82","author":"Xue","year":"2008","journal-title":"J. Virol."},{"key":"ref_9","doi-asserted-by":"crossref","first-page":"418","DOI":"10.1002\/jmv.25681","article-title":"Emerging coronaviruses: Genome structure, replication, and pathogenesis","volume":"92","author":"Chen","year":"2020","journal-title":"J. Med. Virol."},{"key":"ref_10","doi-asserted-by":"crossref","first-page":"522","DOI":"10.1002\/jmv.25700","article-title":"Genomic variance of the 2019-nCoV coronavirus","volume":"92","author":"Ceraolo","year":"2020","journal-title":"J. Med. Virol."},{"key":"ref_11","doi-asserted-by":"crossref","first-page":"104212","DOI":"10.1016\/j.meegid.2020.104212","article-title":"Full-genome evolutionary analysis of the novel corona virus (2019-nCoV) rejects the hypothesis of emergence as a result of a recent recombination event","volume":"79","author":"Paraskevis","year":"2020","journal-title":"Infect. Genet. Evol."},{"key":"ref_12","doi-asserted-by":"crossref","first-page":"730","DOI":"10.1002\/cbic.202000047","article-title":"Learning from the Past: Possible Urgent Prevention and Treatment Options for Severe Acute Respiratory Infections Caused by 2019-nCoV","volume":"21","author":"Morse","year":"2020","journal-title":"ChemBioChem"},{"key":"ref_13","doi-asserted-by":"crossref","first-page":"255","DOI":"10.1007\/978-1-4939-7201-2_18","article-title":"Docking and Virtual Screening in Drug Discovery","volume":"1647","author":"Kontoyianni","year":"2017","journal-title":"Methods Mol. Biol."},{"key":"ref_14","doi-asserted-by":"crossref","first-page":"101","DOI":"10.1016\/j.antiviral.2017.02.007","article-title":"Identification and evaluation of potent Middle East respiratory syndrome coronavirus (MERS-CoV) 3CLPro inhibitors","volume":"141","author":"Kumar","year":"2017","journal-title":"Antivir. Res."},{"key":"ref_15","doi-asserted-by":"crossref","first-page":"915","DOI":"10.1177\/1087057106293295","article-title":"Discovering severe acute respiratory syndrome coronavirus 3CL protease inhibitors: Virtual screening, surface plasmon resonance, and fluorescence resonance energy transfer assays","volume":"11","author":"Chen","year":"2006","journal-title":"J. Biomol. Screen."},{"key":"ref_16","doi-asserted-by":"crossref","first-page":"237","DOI":"10.1146\/annurev-virology-110615-042301","article-title":"Structure, Function, and Evolution of Coronavirus Spike Proteins","volume":"3","author":"Li","year":"2016","journal-title":"Annu. Rev. Virol."},{"key":"ref_17","doi-asserted-by":"crossref","first-page":"476","DOI":"10.1016\/j.bbrc.2004.02.074","article-title":"Analysis of multimerization of the SARS coronavirus nucleocapsid protein","volume":"316","author":"He","year":"2004","journal-title":"Biochem. Biophys. Res. Commun."},{"key":"ref_18","doi-asserted-by":"crossref","first-page":"33","DOI":"10.1186\/1758-2946-3-33","article-title":"Open Babel: An open chemical toolbox","volume":"3","author":"Banck","year":"2011","journal-title":"J. Cheminform."},{"key":"ref_19","doi-asserted-by":"crossref","first-page":"19","DOI":"10.1016\/j.softx.2015.06.001","article-title":"GROMACS: High performance molecular simulations through multi-level parallelism from laptops to supercomputers","volume":"1","author":"Abraham","year":"2015","journal-title":"SoftwareX"},{"key":"ref_20","doi-asserted-by":"crossref","first-page":"455","DOI":"10.1002\/jcc.21334","article-title":"AutoDock Vina: Improving the speed and accuracy of docking with a new scoring function, efficient optimization, and multithreading","volume":"31","author":"Trott","year":"2010","journal-title":"J. Comput. Chem."},{"key":"ref_21","doi-asserted-by":"crossref","first-page":"905","DOI":"10.1038\/nprot.2016.051","article-title":"Computational protein-ligand docking and virtual drug screening with the AutoDock suite","volume":"11","author":"Forli","year":"2016","journal-title":"Nat. Protoc."},{"key":"ref_22","doi-asserted-by":"crossref","first-page":"13190","DOI":"10.1073\/pnas.1835675100","article-title":"The crystal structures of severe acute respiratory syndrome virus main protease and its complex with an inhibitor","volume":"100","author":"Yang","year":"2003","journal-title":"Proc. Natl. Acad. Sci. USA"},{"key":"ref_23","doi-asserted-by":"crossref","first-page":"1690","DOI":"10.1107\/S0907444912039029","article-title":"ScrewFit: Combining localization and description of protein secondary structure","volume":"68","author":"Calligari","year":"2012","journal-title":"Acta Crystallogr. Sect. D Biol. Crystallogr."},{"key":"ref_24","doi-asserted-by":"crossref","first-page":"12997","DOI":"10.1073\/pnas.1601327113","article-title":"SARS-CoV 3CL protease cleaves its C-terminal autoprocessing site by novel subsite cooperativity","volume":"113","author":"Muramatsu","year":"2016","journal-title":"Proc. Natl. Acad. Sci. USA"},{"key":"ref_25","doi-asserted-by":"crossref","first-page":"614","DOI":"10.1128\/CMR.11.4.614","article-title":"Protease inhibitors as antiviral agents","volume":"11","author":"Patick","year":"1998","journal-title":"Clin. Microbiol. Rev."},{"key":"ref_26","doi-asserted-by":"crossref","first-page":"1652","DOI":"10.1002\/anie.200906696","article-title":"Induced-fit binding of the macrocyclic noncovalent inhibitor TMC435 to its HCV NS3\/NS4A protease target","volume":"49","author":"Cummings","year":"2010","journal-title":"Angew. Chem. Int. Ed. Engl."},{"key":"ref_27","doi-asserted-by":"crossref","first-page":"e79","DOI":"10.3346\/jkms.2020.35.e79","article-title":"Case of the Index Patient Who Caused Tertiary Transmission of COVID-19 Infection in Korea: The Application of Lopinavir\/Ritonavir for the Treatment of COVID-19 Infected Pneumonia Monitored by Quantitative RT-PCR","volume":"35","author":"Lim","year":"2020","journal-title":"J. Korean Med. Sci."},{"key":"ref_28","doi-asserted-by":"crossref","unstructured":"Xu, Z., Peng, C., Shi, Y., Zhu, Z., Mu, K., Wang, X., and Zhu, W. (2020). Nelfinavir was predicted to be a potential inhibitor of 2019-nCov main protease by an integrative approach combining homology modelling, molecular docking and binding free energy calculation. bioRxiv.","DOI":"10.1101\/2020.01.27.921627"},{"key":"ref_29","doi-asserted-by":"crossref","first-page":"1260","DOI":"10.1126\/science.abb2507","article-title":"Cryo-EM structure of the 2019-nCoV spike in the prefusion conformation","volume":"367","author":"Wrapp","year":"2020","journal-title":"Science"},{"key":"ref_30","doi-asserted-by":"crossref","first-page":"119","DOI":"10.1038\/cr.2016.152","article-title":"Cryo-electron microscopy structures of the SARS-CoV spike glycoprotein reveal a prerequisite conformational state for receptor binding","volume":"27","author":"Gui","year":"2017","journal-title":"Cell Res."},{"key":"ref_31","doi-asserted-by":"crossref","first-page":"E7348","DOI":"10.1073\/pnas.1707304114","article-title":"Immunogenicity and structures of a rationally designed prefusion MERS-CoV spike antigen","volume":"114","author":"Pallesen","year":"2017","journal-title":"Proc. Natl. Acad. Sci. USA"},{"key":"ref_32","doi-asserted-by":"crossref","first-page":"1026","DOI":"10.1016\/j.cell.2018.12.028","article-title":"Unexpected Receptor Functional Mimicry Elucidates Activation of Coronavirus Fusion","volume":"176","author":"Walls","year":"2019","journal-title":"Cell"},{"key":"ref_33","doi-asserted-by":"crossref","unstructured":"Venkataraman, S., Prasad, B., and Selvarajan, R. (2018). RNA Dependent RNA Polymerases: Insights from Structure, Function and Evolution. Viruses, 10.","DOI":"10.3390\/v10020076"},{"key":"ref_34","doi-asserted-by":"crossref","first-page":"313","DOI":"10.1007\/978-1-4615-5331-1_41","article-title":"Mouse hepatitis virus nucleocapsid protein as a translational effector of viral mRNAs","volume":"440","author":"Tahara","year":"1998","journal-title":"Adv. Exp. Med. Biol."},{"key":"ref_35","doi-asserted-by":"crossref","first-page":"149","DOI":"10.1038\/d41573-020-00016-0","article-title":"Therapeutic options for the 2019 novel coronavirus (2019-nCoV)","volume":"19","author":"Li","year":"2020","journal-title":"Nat. Rev. Drug Discov."},{"key":"ref_36","doi-asserted-by":"crossref","unstructured":"Martinez, M.A. (2020). Compounds with therapeutic potential against novel respiratory 2019 coronavirus. Antimicrob. Agents Chemother., AC.00399-20, Advance online publication.","DOI":"10.1128\/AAC.00399-20"},{"key":"ref_37","doi-asserted-by":"crossref","first-page":"215","DOI":"10.1038\/nrd1331","article-title":"Enfuvirtide: The first therapy to inhibit the entry of HIV-1 into host CD4 lymphocytes","volume":"3","author":"Matthews","year":"2004","journal-title":"Nat. Rev. Drug Discov."},{"key":"ref_38","first-page":"56","article-title":"Clinical efficacy of umifenovir in influenza and ARVI (study ARBITR)","volume":"91","author":"Pshenichnaya","year":"2019","journal-title":"Ter. Arkhiv"},{"key":"ref_39","doi-asserted-by":"crossref","first-page":"339","DOI":"10.1592\/phco.23.3.339.32099","article-title":"Pleconaril, a novel antipicornaviral agent","volume":"23","author":"Florea","year":"2003","journal-title":"Pharmacotherapy"},{"key":"ref_40","doi-asserted-by":"crossref","unstructured":"Bhatnagar, T., Murhekar, M.V., Soneja, M., Gupta, N., Giri, S., Wig, N., and Gangakhedkar, R. (2020). Lopinavir\/ritonavir combination therapy amongst symptomatic coronavirus disease 2019 patients in India: Protocol for restricted public health emergency use. Indian J. Med. Res., Advance online publication.","DOI":"10.4103\/ijmr.IJMR_502_20"},{"key":"ref_41","doi-asserted-by":"crossref","unstructured":"Cao, B., Wang, Y., Wen, D., Liu, W., Wang, J., Fan, G., Ruan, L., Song, B., Cai, Y., and Wei, M. (2020). A Trial of Lopinavir-Ritonavir in Adults Hospitalized with Severe Covid-19. N. Engl. J. Med., Advance online publication.","DOI":"10.1056\/NEJMoa2001282"},{"key":"ref_42","doi-asserted-by":"crossref","unstructured":"Deng, L., Li, C., Zeng, Q., Liu, X., Li, X., Zhang, H., Hong, Z., and Xia, J. (2020). Arbidol combined with LPV\/r versus LPV\/r alone against Corona Virus Disease 2019: A retrospective cohort study. J. Infect., S0163-4453(20)30113-4, Advance online publication.","DOI":"10.1016\/j.jinf.2020.03.002"}],"container-title":["Viruses"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/www.mdpi.com\/1999-4915\/12\/4\/445\/pdf","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2025,10,13]],"date-time":"2025-10-13T13:21:10Z","timestamp":1760361670000},"score":1,"resource":{"primary":{"URL":"https:\/\/www.mdpi.com\/1999-4915\/12\/4\/445"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2020,4,14]]},"references-count":42,"journal-issue":{"issue":"4","published-online":{"date-parts":[[2020,4]]}},"alternative-id":["v12040445"],"URL":"https:\/\/doi.org\/10.3390\/v12040445","relation":{"has-review":[{"id-type":"doi","id":"10.3410\/f.737763491.793573766","asserted-by":"object"}]},"ISSN":["1999-4915"],"issn-type":[{"value":"1999-4915","type":"electronic"}],"subject":[],"published":{"date-parts":[[2020,4,14]]}}}